[ad_1]
The good news about the effectiveness of the Pfizer-Bionic vaccine continues day after day, after it proved effective in limiting the spread of emerging coronavirus infection, providing protection and immunity to the vast majority of those who received the vaccine. vaccine in Israel, as published by Bloomberg, and a British study confirmed that the vaccine reduces the risk of infection after the first dose.
Ugur Shaheen, president of the German company Biontec that developed the Pfizer vaccine, came out with joyous news confirming that whoever receives the vaccine will not become contagious or a carrier of the virus.
Contain the epidemic
He explained in an interview with the German newspaper “Bild”, that “after vaccination with the vaccine, the probability of transmitting the virus, even if you are infected with it, is 92% low. With this information, we now know that we can effectively contain the epidemic if enough people are vaccinated. “
“The light at the end of the tunnel has gotten brighter,” he said. “Once enough people have been vaccinated, we will control the epidemic.”
He added: “The results of the studies done on the Biontec vaccine are much better than I expected, and the statistics are wonderful and show that we are on the right track.”
Lighten the load
Last February, the US company Pfizer and the German company Biontech announced that they had submitted new data to the US Food and Drug Administration (FDA) indicating that the Covid-19 vaccine was stable when stored between minus 25 degrees. and 15 degrees below zero, and They said that the data can allow storage at normal temperatures with refrigeration and freezing devices in pharmacies.
Should the new data be approved, easing the requirements will significantly reduce the transport and storage burden, as the vaccine must currently be stored at minus 70 degrees Celsius, which is especially challenging in low-income countries that do not They have the necessary infrastructure for temperature storage.
Notably, the Pfizer and Biontech vaccine, along with the Moderna vaccine, were granted emergency use permission in the United States and are being widely distributed as part of comprehensive vaccination efforts in the country.
